Table 1.

Patient information

	Patient number
	1	2	3	4	5	6	7	8	9	10	11
Age	76	55	70	85	76	76	64	79	54	73	50
Sex	M	M	M	F	F	M	M	M	M	M	M
Diagnosis	Relapsed CLL	Relapsed CLL, 17p	Relapsed CLL, 13q	Relapsed 17p CLL	Upfront SLL	Relapsed CLL 11q	Relapsed WM	Relapsed CLL	CLL	CLL	CLL
Hb, g/L	122	140	131	116	120	148	177	140	143	159	140
Platelets, × 109/L	88	196	99	179	213	73	217	146	179	113	171
Concurrent medication	Aspirin	None	Plavix 75 mg qd	None	Mobic 15 mg prn	None	Aspirin	None	None	None	None
Duration of Btk therapy	19 mo, IB 420 mg qd	55 mo, IB 420 mg qd	29 mo, IB 420 mg qd	55 mo, IB 420 mg qd	19.5 mo, BGB 160 mg bid	31 mo, IB 420 mg qd	36 mo, BGB 160 mg bid	24 mo, BGB 160 mg bid	67 mo, IB	42 mo, BGB	33 mo, BGB
Active bleeding at time of test	None	None	None	None	None	None	None	None	None	None	None
Bleeding with Btk treatment	Grade 1 easy bruising	None	Grade 1 bruising	Grade 2 bleeding	Grade 1 bruising	None	None	None	Grade 1 bruising	Grade 1 bruising	Grade 1 bruising
Disease response	PR	PR	CR	CR	PR	CR	PR	PR	CR	CR	PR

bid, twice daily; BGB, zanubrutinib; CR, complete remission; F, female; IB, ibrutinib; M, male; PR, partial remission; prn, taken on an as-needed basis; qd, daily; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.